B
Barbara Pistilli
Researcher at Institut Gustave Roussy
Publications - 169
Citations - 2907
Barbara Pistilli is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 20, co-authored 83 publications receiving 1912 citations. Previous affiliations of Barbara Pistilli include European Institute of Oncology & Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Denise A. Yardley,Shinzaburo Noguchi,Kathleen I. Pritchard,Howard A. Burris,José Baselga,Michael Gnant,Gabriel N. Hortobagyi,Mario Campone,Barbara Pistilli,Martine Piccart,Bohuslav Melichar,Katarína Petráková,Francis P. Arena,Frans L. G. Erdkamp,Wael A. Harb,Wentao Feng,Ayelet Cahana,Tetiana Taran,David Lebwohl,Hope S. Rugo +19 more
TL;DR: The addition of everolimus to exemestane markedly prolonged PFS in patients with HR+ advanced BC with disease recurrence/progression following prior NSAIs, and results further support the use ofEverolimus plus exemstane in this patient population.
Journal ArticleDOI
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga,Seock–Ah –A Im,Hiroji Iwata,Javier Cortes,Michele De Laurentiis,Zefei Jiang,Carlos L. Arteaga,Walter Jonat,Mark Clemons,Yoshinori Ito,Ahmad Awada,Stephen Chia,Agnieszka Jagiełło-Gruszfeld,Barbara Pistilli,Ling Ming Tseng,Sara A. Hurvitz,Norikazu Masuda,Masato Takahashi,Peter Vuylsteke,Soulef Hachemi,Bharani Dharan,Emmanuelle di Tomaso,Patrick Urban,Cristian Massacesi,Mario Campone +24 more
TL;DR: This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in patients with advanced breast cancer, including an evaluation of the PI3K pathway activation status as a biomarker for clinical benefit.
Journal ArticleDOI
Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study
Hatem A. Azim,Niels Kroman,Marianne Paesmans,Shari Gelber,Nicole Rotmensz,Lieveke Ameye,Leticia De Mattos-Arruda,Barbara Pistilli,Alvaro Pinto,Maj-Britt Jensen,Octavi Cordoba,Evandro de Azambuja,Aron Goldhirsch,Martine Piccart,Fedro A. Peccatori +14 more
TL;DR: Pregnancy after ER-positive BC does not seem to reduce the risk of BC recurrence, and DFS in the whole population, and overall survival (OS) were secondary objectives.
Journal ArticleDOI
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
Arlindo R. Ferreira,Arlindo R. Ferreira,A. Di Meglio,Barbara Pistilli,Arnauld S. Gbenou,Mayssam El-Mouhebb,Sarah Dauchy,Cécile Charles,Florence Joly,Sibille Everhard,Matteo Lambertini,Charles Coutant,Paul-Henri Cottu,Florence Lerebours,Thierry Petit,Florence Dalenc,Philippe Rouanet,Antoine Arnaud,Anne-Laure Martin,J. Berille,P.A. Ganz,Ann H. Partridge,Suzette Delaloge,Stefan Michiels,Fabrice Andre,Ines Vaz-Luis +25 more
TL;DR: QoL deterioration persisted at 2 years after diagnosis with different trajectories by treatment received; in premenopausal patients, CT, despite only a non-significant trend for deteriorated C30-SumSc, was more frequently associated with QoL domains deterioration than ET, whereas in postmenopausal Patients, ET was morerequentlyassociated with QOL deterioration.
Journal ArticleDOI
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Mario Giuliano,Mario Giuliano,Francesco Schettini,Francesco Schettini,Carla Rognoni,Manuela Milani,Guy Jerusalem,Thomas Bachelot,Michelino De Laurentiis,Guglielmo Thomas,Pietro De Placido,Grazia Arpino,Sabino De Placido,Massimo Cristofanilli,Antonio Giordano,Fabio Puglisi,Barbara Pistilli,Aleix Prat,Lucia Del Mastro,Sergio Venturini,Sergio Venturini,Daniele Generali +21 more
TL;DR: The data support treatment guideline recommendations involving the new combinations of hormone therapies plus targeted therapies as first-line or second-line treatments, or in both settings, in women with hormone-receptor-positive, HER2-negative metastatic breast cancer.